Matthew H Wilson

Title: Matthew H. Wilson and Perforin-Deficient T-Cell Technology.

Introduction

Matthew H. Wilson is an inventor associated with Vanderbilt University in Nashville, Tennessee. His patent work concerns engineered T cells that lack Perforin function and their potential use as targeted peptide-delivery platforms. The available information identifies 1 patent associated with him.

Latest Patents

Wilson’s listed patent, “Lymphocytes Lacking Perforin Function,” describes T cells engineered to lose, reduce, or inhibit Perforin activity. Because Perforin-deficient T cells lack a conventional cytotoxic effector function, they are not designed to kill target cells through Perforin-dependent pathways. The disclosure instead focuses on their ability to home to target tissues, persist, and proliferate.

The proposed platform uses antigen recognition to direct these cells to tumors or other tissues, where they may deliver anti-cancer, pre-immune, or therapeutic peptides. The approach aims to enable targeted delivery without directly destroying the tissue through conventional Perforin-mediated cytotoxicity.

Career Highlights

Wilson’s identified patent reflects research at the intersection of cellular engineering, immunology, and therapeutic delivery. His work explores how modifying an immune cell’s function may support targeted treatment strategies.

Collaborations

Richard T. O’Neil is identified as Wilson’s coworker. The available information does not specify their particular roles or contributions to the patent.

Conclusion

Matthew H. Wilson’s patent describes a potential therapeutic platform that uses Perforin-deficient T cells to deliver peptides to selected tissues while avoiding direct Perforin-dependent cell killing.